Ligand Pharmaceuticals Inc. to Receive $2 Million Milestone Payment From Merck & Co., Inc. Triggered by Initiation of Phase 2b/3 Trial of Dinaciclib
Published: Oct 22, 2012
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it will receive a $2 million milestone payment from Merck, known as MSD outside the United States and Canada, under the terms of a development and license collaboration for the development of dinaciclib. This milestone payment is triggered by the initiation of a Phase 2b/3 adaptive clinical trial for dinaciclib for the treatment of patients with refractory chronic lymphocytic leukemia (CLL).